Medicines360 and Pharma Dynamics have launched AVIBELA, South Africa’s first generic levonorgestrel 52 mg intrauterine device (IUD), significantly enhancing access to long-acting reversible contraception (LARC) and addressing heavy menstrual bleeding (HMB) in the region. AVIBELA boasts over 99% effectiveness in pregnancy prevention for up to six years, aligning with the approved usage duration in South Africa. This initiative is part of a broader strategy to bridge the gap between scientific innovation and practical healthcare delivery, as highlighted by Kelly Dannucci, Senior Director of Global Access at Medicines360.

The introduction of AVIBELA is crucial given the low IUD uptake in South Africa, which stands at approximately 1.9% of the national contraceptive method mix. Despite nine million women using modern contraceptives, barriers such as high upfront costs and limited provider training have hindered IUD adoption. With 64% of pregnancies being unplanned, improving access to effective contraception is a pressing public health concern. The availability of an affordable, clinically equivalent generic IUD like AVIBELA aims to mitigate these barriers, providing women with more options for contraception and menstrual health management.

The launch of AVIBELA has significant implications for the field of reproductive health and may shift current research paradigms surrounding contraceptive options. By demonstrating that a cost-effective, clinically validated IUD can be made widely accessible, it sets a precedent for future developments in long-acting contraceptives. This could accelerate timelines for drug development and regulatory approval processes for similar products, ultimately enhancing patient choice and outcomes in reproductive health.

Source: globenewswire.com